INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/19449

Files in this item

File Description Format
PDF Rondelli D MPD-RC 101 manuscript Blood 2014.pdf (367KB) (no description provided) PDF
Title: MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Author(s): Rondelli, Damiano; Goldberg, Judith D.; Isola, Luis; Price, Leah S.; Shore, Tsiporah B.; Boyer, Michael; Bacigalupo, Andrea; Rambaldi, Alessandro; Scarano, Marco; Klisovic, Rebecca B.; Gupta, Vikas; Andreasson, Bjorn; Mascarenhas, John; Wetzler, Meir; Vannucchi, Alessandro M.; Prchal, Josef T.; Najfeld, Vesna; Orazi, Attilio; Weinberg, Rona S.; Miller, Crystal; Barosi, Giovanni; Silverman, Lewis R.; Prosperini, Giuseppe; Marchioli, Roberto; Hoffman, Ronald
Abstract: From 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF) preceded by essential thrombocythemia or polycythemia vera were enrolled into a prospective phase 2 clinical trial of reduced-intensity allogeneic hematopoietic stem cell transplantation (AHSCT), Myeloproliferative Disorder Research Consortium 101 trial. The study included patients with sibling donors (n = 32) receiving fludarabine/melphalan (FluMel) as a preparative regimen and patients with unrelated donors (n = 34) receiving conditioning with FluMel plus anti-thymocyte globulin (ATG). Patient characteristics in the 2 cohorts were similar. Engraftment occurred in 97% of siblings and 76% of unrelated transplants, whereas secondary graft failure occurred in 3% and 12%, respectively. With a median follow-up of 25 months for patients alive, the overall survival (OS) was 75% in the sibling group (median not reached) and 32% in the unrelated group (median OS: 6 months, 95% confidence interval [CI]: 3, 25) (hazard ratio 3.9, 95% CI: 1.8,8.9) (P < .001). Nonrelapse mortality was 22% in sibling and 59% in unrelated AHSCT. Survival correlated with type of donor, but not with the degree of histocompatibility match, age, or JAK2V617F status. In patients with MF with sibling donors, AHSCT is an effective therapy, whereas AHSCT from unrelated donors with FluMel/ATG conditioning led to a high rate of graft failure and limited survival. This trial was registered at www.clinicaltrials.gov as #NCT00572897.
Issue Date: 2014
Publisher: American Society of Hematology
Citation Info: Rondelli, D., Goldberg, J. D., Isola, L., Price, L. S., Shore, T. B., Boyer, M., Bacigalupo, A., Rambaldi, A., Scarano, M., Klisovic, R. B., Gupta, V., Andreasson, B., Mascarenhas, J., Wetzler, M., Vannucchi, A. M., Prchal, J. T., Najfeld, V., Orazi, A., Weinberg, R. S., Miller, C., Barosi, G., Silverman, L. R., Prosperini, G., Marchioli, R. and Hoffman, R. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014. 124(7): 1183-1191. 10.1182/blood-2014-04-572545.
Type: Article
URI: http://hdl.handle.net/10027/19449
ISSN: 0006-4971
Sponsor: This study was supported by National Institutes of Health, National Cancer Institute grant 1 P01 CA108671-01A2 (principal investigator: R.H.).
Date Available in INDIGO: 2015-06-03
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 225
China 74
Russian Federation 42
Ukraine 17
Germany 8

Browse

My Account

Information

Access Key